<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Great Lakes Pharmaceuticals</title>
	<atom:link href="http://www.glpharma.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.glpharma.com</link>
	<description>Effective Antimicrobial Antibiofilm Therapies</description>
	<lastBuildDate>Mon, 06 Feb 2012 17:10:47 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>May 1, 2008</title>
		<link>http://www.glpharma.com/2011/10/26/may-1-2008/</link>
		<comments>http://www.glpharma.com/2011/10/26/may-1-2008/#comments</comments>
		<pubDate>Wed, 26 Oct 2011 23:17:17 +0000</pubDate>
		<dc:creator>sa</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://64.78.0.251/?p=144</guid>
		<description><![CDATA[ Cleveland, OH, May 1, 2008 – Great Lakes Pharmaceuticals, Inc. announced today the completion of Series A $2.4 million equity financing led by Ohio investment funds including the North Coast Angel Fund JumpStart Inc., Everett Partners, Ltd, Ohio TechAngel Fund and Case Technology Ventures. The Company intends to use the funds to finalize the pre-clinical development and initiate pivotal clinical study of B-Lock™, an antimicrobial and heparin-free antithrombotic catheter lock solution. <a href="/docs/20080501-GL-Funding-Press-Release.pdf">More...PDF(42Kb)</a> [...]]]></description>
			<content:encoded><![CDATA[<p><a href="/docs/20080501-GL-Funding-Press-Release.pdf">Great Lakes Pharmaceuticals, Inc. Announces $2.4 Million Equity Financing</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.glpharma.com/2011/10/26/may-1-2008/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>January 30, 2008</title>
		<link>http://www.glpharma.com/2011/10/26/january-30-2008/</link>
		<comments>http://www.glpharma.com/2011/10/26/january-30-2008/#comments</comments>
		<pubDate>Wed, 26 Oct 2011 22:43:15 +0000</pubDate>
		<dc:creator>sa</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://64.78.0.251/?p=136</guid>
		<description><![CDATA[Cleveland, Ohio, (January 30, 2008) – Great Lakes Pharmaceuticals, Inc. announced today that it has entered into exclusive license agreements with The Board of Regents of The University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”), and Wake Forest University Health Sciences (“WFUHS"). <a href="/docs/20080130-GL-License-Press-Release.pdf">More...PDF(43Kb)</a> [...]]]></description>
			<content:encoded><![CDATA[<p><a href="/docs/20080130-GL-License-Press-Release.pdf">Great Lakes Pharmaceuticals, Inc. Announces the Signing of Exclusive License Agreements</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.glpharma.com/2011/10/26/january-30-2008/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>July 26, 2010</title>
		<link>http://www.glpharma.com/2011/10/23/july-26-2010-2/</link>
		<comments>http://www.glpharma.com/2011/10/23/july-26-2010-2/#comments</comments>
		<pubDate>Sun, 23 Oct 2011 17:11:30 +0000</pubDate>
		<dc:creator>sa</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://64.78.0.251/?p=62</guid>
		<description><![CDATA[CLEVELAND, OH--(Marketwire - July 26, 2010) - Great Lakes Pharmaceuticals, Inc. ("Great Lakes") announced today the completion of a $3.1 million Series B equity financing led by Charter Life Sciences. <a href="/docs/2010-07-26-Equity-Financing.pdf">More...PDF(90Kb)</a> [...]]]></description>
			<content:encoded><![CDATA[<p><a href="/docs/2010-07-26-Equity-Financing.pdf">Great Lakes Pharmaceuticals, Inc. Announces $3.1 Million Equity Financing Led by Charter Life Sciences</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.glpharma.com/2011/10/23/july-26-2010-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>June 29, 2009</title>
		<link>http://www.glpharma.com/2011/10/23/june-29-2009/</link>
		<comments>http://www.glpharma.com/2011/10/23/june-29-2009/#comments</comments>
		<pubDate>Sun, 23 Oct 2011 17:10:41 +0000</pubDate>
		<dc:creator>sa</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://64.78.0.251/?p=59</guid>
		<description><![CDATA[Beachwood, OH - (July 29, 2009) - Great Lakes Pharmaceuticals, Inc. announced that the Company has received a Notice of Award from the National Institutes of Health (NIH), National Heart, Lung, And Blood Institute (NHLBI) in support of the project "Development of B-Lock an antibiofilm catheter lock product". The $2.6 million grant will support efforts to move the Company's B-Lock™, an antimicrobial catheter lock solution, forward to human clinical trial testing for the prevention of infections related to central venous catheters. <a href="/docs/20090729-GL-NIH-Grant-Notice.pdf">More... (12Kb)</a> [...]]]></description>
			<content:encoded><![CDATA[<p><a href="/docs/20090729-GL-NIH-Grant-Notice.pdf">Great Lakes Pharmaceuticals, Inc. announces $2.6 million award from National Institutes of Health</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.glpharma.com/2011/10/23/june-29-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>June 30, 2008</title>
		<link>http://www.glpharma.com/2011/10/23/june-30-2008/</link>
		<comments>http://www.glpharma.com/2011/10/23/june-30-2008/#comments</comments>
		<pubDate>Sun, 23 Oct 2011 17:03:42 +0000</pubDate>
		<dc:creator>sa</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://64.78.0.251/?p=53</guid>
		<description><![CDATA[Beachwood, Ohio - Jun 30, 2008 (PRN): Great Lakes Pharmaceuticals, Inc. announced today that the company has received Phase One, $ 100,000 Fast Track Small Business Innovative Research (SBIR) grant from the National Institute of Health (NIH). <a href="/docs/2008-06-30-SBIR-Grant-NIH.pdf">More...PDF(71Kb)</a> [...]]]></description>
			<content:encoded><![CDATA[<p><a href="/docs/2008-06-30-SBIR-Grant-NIH.pdf">Great Lakes Pharmaceuticals, Inc. Receives Fast Track SBIR Grant Award from NIH</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.glpharma.com/2011/10/23/june-30-2008/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

